UD professor part of NIH-funded project to create artificial salivary glands

NewsGuard 100/100 Score

University of Delaware professor Xinqiao Jia is part of a research team breaking new ground in the creation of artificial salivary glands.

Funded through a $2.5 million grant from the National Institutes of Health, the research team hopes the work will lead to new solutions for Xerostomia, or dry mouth, an inevitable consequence of radiation treatment for head and neck cancers.

The four-year project is a collaborative effort between researchers at Rice University, the University of Delaware and Christiana Care Health System. Principal investigators named to the project include:

Cindy Farach-Carson, vice provost for translational bioscience and professor of biochemistry and cell biology at Rice University; Xinqiao Jia, associate professor of materials science and engineering and biomedical engineering at UD; and Robert Witt, M.D., chief of the multidisciplinary head and neck oncology clinic at Christiana Care's Helen F. Graham Cancer Center.

Head and neck cancer patients often undergo radiation as an early course of treatment. Such treatment often destroys the saliva-producing cells in the mouth. This side effect causes dry mouth which can lead to severe dental issues, as well as difficulty swallowing, speaking and eating, and overall discomfort.

To date, current therapies in this area have proven ineffective over the long term.

"Few in the research community have applied tissue engineering strategies to the problem. Our hope is that by assembling a strategic team with engineering, biological and clinical expertise, we can make headway and offer new hope to patients suffering from this condition," said Jia, a tissue engineering expert.

In previous work the research team developed methods for isolating and growing salivary cells, which are responsible for water and enzyme production, in the lab prior to radiation. These cells form 3D secretory structures when cultured in biologically relevant hydrogels.

At UD, the Jia Group will develop hydrogels that will be used as instructive matrices to guide the salivary cells through morphogenesis processes and potentially organize them into functional salivary glands. Jia explained that the hydrogels can be "tuned" to match the structure and properties of the native tissues in salivary glands, increasing the potential for success.

Working with collaborators at the Helen F. Graham Center's Center for Translational Cancer Research, the team hopes the work will translate into reliable methods to produce artificial salivary glands.

Doctors will culture a patient's cells prior to radiation treatment and then re-implant the salivary glands grown from the patients' own cells back into the mouth following treatment.

"The goal is to help cancer survivors overcome dry mouth problems and improve their quality of life," Jia added.

"Interdisciplinary teams permit research groups to more effectively solve complex problems and this project highlights the synergy between the basic, applied and clinical aspects of bioengineering research," added Kristi Kiick, deputy dean of UD's College of Engineering. "As more faculty engage in these types of interdisciplinary programs and partnerships, the impact and visibility of the University's research will continue to grow."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
First UK real-world study shows promise for sacituzumab govitecan in metastatic breast cancer